Invest in intelligence that delivers

Amjevita leads Humira biosimilars in clinician comfort as rheumatologists remain wary

Only half of rheumatologists are “extremely comfortable” prescribing the Humira biosimilar Amjevita, while just 16% can say the same for all other adalimumab biosimilars combined, according to a market analysis from Spherix Global Insights. For reference, 83% of rheumatologists included in the analysis reported being “extremely comfortable” prescribing originator Humira (adalimumab, AbbVie). This yawning gap underscores […]

Market Study Reports Secukinumab Emerged as a Leading Treatment for HS

To gauge the impact and evolving landscape of HS treatment post-secukinumab approval, Spherix Global Insights conducted research with more than 100 US dermatologists. In a significant development for patients with hidradenitis suppurativa (HS), the FDA granted approval to secukinumab (Cosentyx, Novartis) last fall. This marked a milestone as secukinumab became the second biologic, alongside adalimumab […]

Novartis’ Cosentyx Shows Promising Early Progress in Treating Hidradenitis Suppurativa, Poised for Significant Future Adoption at the Expense of AbbVie’s Humira

Despite the expanded armamentarium, Cosentyx has not impacted dermatologists’ perceived unmet need for new HS treatment options, according to Spherix Global Insights. [Exton, PA., January 10, 2024] — In late October 2023, the FDA granted approval to Novartis’ Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as the second biologic approved alongside AbbVie’s Humira […]

BMS Attributes Sotyktu Falling Short of Growth Expectations to Access, but Recent Spherix Global Insights’ Data Suggest Safety Concerns Are More of a Barrier to Increased Uptake

US dermatologists’ perceptions and experience with Sotyktu likely impacting their take on the entire TYK2 class for the treatment of plaque psoriasis. Exton, PA., December 7, 2023 –   While access took the forefront of BMS’ response to Sotyktu (deucravacitinib) not meeting growth expectations during the company’s Q3 earnings call, practicing dermatologists in Spherix research highlight […]

Eli Lilly’s Olumiant and Pfizer’s Litfulo Strengthen Alopecia Areata Arsenal, Yet Resounding Opportunity for JAK Expansion and New Assets in Development Remain

Despite little prescriber differentiation between the JAKs, including satisfaction and manufacturer perceptions, Olumiant is projected to maintain a significant market lead over Litfulo.  [Exton PA, November 15, 2023] — Spherix Global Insights has been monitoring the alopecia areata (AA) market for the past four years and has found that the entry of JAK inhibitors has […]

Amgen’s Amjevita Remains the Frontrunner in the US Adalimumab Biosimilars Market, Despite Increased Competition, According to Spherix Global Insights.

Boehringer Ingelheim’s Cyltezo has a slight competitive edge over other concurrent biosimilar launches on certain key performance metrics, though prescriber future projections show little differentiation in use among the recent entrants. Exton, PA, September 14, 2023 — This summer ushered in the highly anticipated introduction of a multitude of additional adalimumab biosimilars to the dynamic […]

With Little Remaining Unmet Need for Injectable Biologics for the Treatment of Plaque Psoriasis, US Dermatologists Report the Future is Oral, According to Spherix Global Insights

Despite the increased efficacy of BMS’ Sotyktu over Amgen’s Otezla, dermatologists continue to express a desire for additional oral agents that bring enhanced safety and efficacy. Exton, PA August 31, 2023 – The biologic treatment armamentarium for plaque psoriasis has arguably experienced some of the most successful developments in recent autoimmune history. With the entry […]

Sign up for alerts, market insights and exclusive content in your inbox.

Spherix is excited to announce our expansion into an additional, rapidly evolving specialty market:

HEMATOLOGY

Throughout 2024, we will be publishing over
10 groundbreaking studies covering a wide range of indications within classical hematology.